Human Ornithine carbamoyltransferase, mitochondrial(OTC) ELISA kit

Code CSB-EL017270HU
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
ornithine carbamoyltransferase
Alternative Names
EC 2.1.3.3 ELISA Kit; MGC129967 ELISA Kit; MGC129968 ELISA Kit; MGC138856 ELISA Kit; OCTD ELISA Kit; Ornithine Carbamoyltransferase ELISA Kit; Ornithine carbamoyltransferase mitochondrial ELISA Kit; Ornithine carbamoyltransferase, mitochondrial ELISA Kit; Ornithine transcarbamylase ELISA Kit; Otc ELISA Kit; OTC_HUMAN ELISA Kit; OTCase ELISA Kit
Abbreviation
OTC
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates, cell lysates
Detection Range
1.25 mU/mL-80 mU/mL
Sensitivity
0.312 mU/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Metabolism
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human OTC in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:1 Average % 84
Range % 80-89
1:2 Average % 98
Range % 94-103
1:4 Average % 85
Range % 81-89
1:8 Average % 99
Range % 94-104
Recovery
The recovery of human OTC spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 100 95-105
EDTA plasma (n=4) 86 83-89
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
mU/ml OD1 OD2 Average Corrected
80 1.964 1.900 1.932 1.748
40 1.764 1.789 1.777 1.593
20 1.579 1.502 1.541 1.357
10 1.257 1.201 1.229 1.045
5 0.901 0.931 0.916 0.732
2.5 0.591 0.587 0.589 0.405
1.25 0.362 0.371 0.367 0.183
0 0.188 0.180 0.184  
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

The Human Ornithine carbamoyltransferase, mitochondrial (OTC) ELISA kit is an essential tool for researchers in the field of metabolism. This high-quality kit is designed to accurately detect and quantify the Ornithine transcarbamylase, mitochondrial protein (OTC) in a range of human samples including serum, plasma, tissue homogenates, and cell lysates.

With a detection range of 1.25 mU/mL-80 mU/mL and a sensitivity of 0.312 mU/mL, this kit provides reliable and precise results in a short assay time of 1-5h. The sample volume required for analysis is minimal, only 50-100ul, making it a cost-effective and efficient solution for detecting OTC levels in human samples.

The OTC ELISA kit operates on a sandwich assay principle, providing a quantitative measurement of OTC protein in your samples. The detection wavelength for this assay is 450 nm, and it has been optimized to work with samples from human species. This kit is an ideal tool for researchers studying metabolism and can provide accurate and reproducible results.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Catalyzes the second step of the urea cycle, the condensation of carbamoyl phosphate with L-ornithine to form L-citrulline. The urea cycle ensures the detoxification of ammonia by converting it to urea for excretion.
Gene References into Functions
  1. Whole exome sequencing successfully identified disease-causing mutations including two novel ones: the c.209_210delAA (p.Lys70Argfs*17) and the c.850T>A (p.Tyr284Asn). PMID: 30223008
  2. indicate that the proportion of about 20-30% of hepatocytes expressing the functional OTC protein is not sufficient to maintain metabolic stability. X-inactivation ratios assessed in liver biopsies taken from heterozygous females with X-linked disorders should not be considered representative of the whole liver PMID: 29623395
  3. The measurement of serum ornithine carbamoyltransferase concentration may provide a useful marker of disease severity, and thus could be a useful marker for a high risk of hepatocellular carcinoma occurrence. PMID: 28824294
  4. Low expression of OTC is associated with glioblastoma. PMID: 27431689
  5. In Korean patients with OTC deficiency, mutations in OTC are genetically heterogeneous. PMID: 25994866
  6. Sanger sequencing of the ornithine transcarbamylase (OTC) gene revealed a novel hemizygous deletion at the fourth nucleotide of intron 4 (c.386+4delT) in a child with hyperammonemia and his asymptomatic mother. PMID: 26446336
  7. Ornithine transcarbamylase deficiency was genetically heterogeneous in seven Korean patients with confirmed ornithine transcarbamylase deficiency diagnosis by biochemical findings and/or genetic analysis, together with two novel mutations in the OTC gene PMID: 25011434
  8. The corresponding OTC tissue enzyme activities were between 3-6% of normal control in mouse and human liver. The use of the cryptic splice sites was reproduced in minigenes carrying murine or human mutant sequences PMID: 25853564
  9. OTC mutation and phenotype in ornithine transcarbamylase deficiency PMID: 26059767
  10. aim of this study was to provide clues for recognition of OTCD in adults and analyze the environmental factors that, interacting with OTC gene mutations, might have triggered acute clinical manifestations PMID: 25026867
  11. HNF-4alpha most likely plays an essential role in the initiation of OTC transcription in human. PMID: 25056436
  12. Data indicate that all of the three patients have carried ornithine transcarbamylase gene mutations, patients 1 and 2 were both hemizygous for mutation c.586G> A(p.D196N). PMID: 25297582
  13. V339G and W332S mutations of OTC have been discovered for the first time PMID: 24711021
  14. carriers of the ornithine transcarbamylase (OTC) mutation are at risk for developing hyperammonemia coma during the postpartum period and at times of metabolic stress. PMID: 21956151
  15. In patients with a clinical and biochemical presentation of OTCD and negative OTC sequencing, whole genome or targeted chromosomal microarray analysis (CMA) with coverage of the OTC and neighboring genes should be performed as a reflex test. PMID: 20817516
  16. Mutations in the regulatory regions of OTC can lead to ornithine carbamoyltransferase deficiency and should be included in genetic testing. PMID: 20127982
  17. These results indicate that mutant alleles with late-onset OCT deficiency syndrome have recurrently arisen, have been retained in some populations, and some appear to hvae a common ancestor. PMID: 19893582
  18. deficiency in ornithine carbamoyltransferase enzymatic function conferred by the R40H mutation is likely caused by enhanced degradation of the preprotein in the cytosol. PMID: 11768581
  19. ornithine transcarbamylase (OTC) deficiency: review of mutations and polymorphisms in the human ornithine transcarbamylase gene PMID: 11793468
  20. seven novel missense mutations, two splice-site mutations, two microdeletions and a polymorphic amino acid substitution in the gene for ornithine transcarbamylase (OTC) in patients with OTC deficiency PMID: 11793483
  21. novel mutations in the ornithine transcarbamylase gene PMID: 12083811
  22. Haplotype analysis and phylogeny of polymorphisms of this protein were studied in two male populations. PMID: 12516615
  23. Using 2 (CA)n flanking markers of the OTC gene (DXS997 & DXS1068), the haplotypic background of 37 different mutational events was defined & compared with random control chromosomes. 1 particular haplotype is a risk factor for carrying OTC mutations. PMID: 15300856
  24. Mutations in the human ornithine transcarbamylase (OTC) gene is detected in patients with Hyperammonemia-induced encephalopathy due to ornithine transcarbamylase deficiency. PMID: 15692798
  25. Novel mutations within the OTC gene are associated with Ornithine transcarbamylase (OTC) deficiency disorder. PMID: 16786505
  26. Novel mutations p.Leu9X, p.Arg26Pro, p.Gly100Arg, p.Met205Thr, p.Lys221Asn, p.Asp249Gly, p.Phe281Ser, p.Val323Met, c.571delC, c.853delC, and c.796-805del are associated with OTC deficiency. PMID: 17041896
  27. Describe a contiguous gene syndrome involving the RPGR, OTC and TM4SF2 genes in a male patient with severe neonatal ornithine transcarbamylase deficiency. PMID: 17570074
  28. Data show that OCT/ALT is a potent indicator for the diagnosis and the prognosis of hepatocellular carcinoma. PMID: 17570354
  29. our results suggest the involvement of a new pathway in AD brains involving the urea cycle. PMID: 17893704
  30. In ten families with late-onset ornithine transcarbamylase (OTC) deficiency in male patients, three mutant alleles-R40H, R277W, and Y55D-were identified. PMID: 18030415
  31. Two known and three novel mutations of the ornithine transcarbamylase (OTC) gene are reported in five Japanese patients with OTC deficieny including two neonatal-onset, one late-onset, and two symptomatic female patients. PMID: 18204299
  32. The rs5963409 minor allele was weakly but significantly associated with an increased risk of developing AD. PMID: 18983895
  33. Deletions and gene rearrangements of OTC gene are associated with Ornithine Carbamoyltransferase Deficiency Disease. PMID: 19138872
  34. Hypocitrullinemia in expanded newborn screening is not a reliable marker for OTCD. PMID: 19359120
  35. the identification of novel disease-causing mutations in Ornithine transcarbamylase deficiency and increases the knowledge on possible mutational mechanisms generating deletions in ornithine transcaramylase. PMID: 19475717
  36. OTC rs5963409 polymorphism may be associated with hypertension and coronary vasomotion in males PMID: 19574962

Show More

Hide All

Involvement in disease
Ornithine carbamoyltransferase deficiency (OTCD)
Subcellular Location
Mitochondrion matrix.
Protein Families
ATCase/OTCase family
Tissue Specificity
Mainly expressed in liver and intestinal mucosa.
Database Links

HGNC: 8512

OMIM: 300461

KEGG: hsa:5009

STRING: 9606.ENSP00000039007

UniGene: Hs.117050

CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1